Editorial
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Mar 28, 2024; 30(12): 1670-1675
Published online Mar 28, 2024. doi: 10.3748/wjg.v30.i12.1670
Advancements in medical treatment for pancreatic neuroendocrine tumors: A beacon of hope
Somdatta Giri, Jayaprakash Sahoo
Somdatta Giri, Jayaprakash Sahoo, Department of Endocrinology and Metabolism, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, 605006, India
Author contributions: Giri S did the literature search, wrote the first draft and gave intellectual input; Sahoo J conceptualized the work, supervised the writing, gave intellectual inputs, and critically revised the manuscript.
Conflict-of-interest statement: All authors have no conflict of interest to report.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jayaprakash Sahoo, MBBS, MD, DM, Full Professor, Department of Endocrinology and Metabolism, Jawaharlal Institute of Postgraduate Medical Education and Research, D. Nagar, Gorimedu, JIPMER Campus, Puducherry 605006, India. jppgi@yahoo.com
Received: December 28, 2023
Peer-review started: December 28, 2023
First decision: January 19, 2024
Revised: January 29, 2024
Accepted: March 7, 2024
Article in press: March 7, 2024
Published online: March 28, 2024
Processing time: 90 Days and 17.9 Hours
Abstract

This editorial highlights the remarkable advancements in medical treatment strategies for pancreatic neuroendocrine tumors (pan-NETs), emphasizing tailored approaches for specific subtypes. Cytoreductive surgery and somatostatin analogs (SSAs) play pivotal roles in managing tumors, while palliative options such as molecular targeted therapy, peptide receptor radionuclide therapy, and chemotherapy are reserved for SSA-refractory patients. Gastrinomas, insulinomas, glucagonomas, carcinoid tumors and VIPomas necessitate distinct thera-peutic strategies. Understanding the genetic basis of pan-NETs and exploring immunotherapies could lead to promising avenues for future research. This review underscores the evolving landscape of pan-NET treatment, offering renewed hope and improved outcomes for patients facing this complex disease.

Keywords: Pancreatic neuroendocrine tumor; Medical management; Somatostatin analog; Immunotherapy; Everolimus

Core Tip: The evolving landscape of pancreatic neuroendocrine tumor treatment showcases tailored approaches based on tumor subtype. Cytoreductive surgery and somatostatin analogs are pivotal, whereas peptide receptor radionuclide therapy and molecular targeted agents are offering hope for refractory cases. Understanding genetic markers and exploring immunotherapies open promising avenues for future research.